Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Shanna Dewaele

Awards & Distinctions

14 Results

2023

Mammalian target of rapamycin inhibition enhances delivery and activity of antisense oligonucleotides in uveal melanoma cells

Shanna DewaeleLouis DelhayeBoel De PaepeBram BogaertRamiro MartinezJasper AnckaertNurten YigitJustine NuytensRudy Van CosterSven Eyckerman et al.

A1 Journal Article in NUCLEIC ACID THERAPEUTICS

2022

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival

Shanna DewaeleLouis DelhayeBoel De PaepeEric de Bony de LavergneJilke De WildeKatrien VanderheydenJasper AnckaertNurten YigitJustine NuytensEveline Vanden Eynde et al.

A1 Journal Article in ONCOGENE

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival (Sept, 10.1038/s41388-021-02006-x, 2021)

Shanna DewaeleLouis DelhayeBoel De PaepeEric James de BonyJilke De WildeKatrien VanderheydenJasper AnckaertNurten YigitJustine NuytensEveline Vanden Eynde et al.

Unraveling the therapeutic potential of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaelePieter MestdaghJo Vandesompele

2020

mTor inhibitor GDC-0349 improves ASO induced SAMMSON knock down resulting in enhanced anti-tumor efficacy in uveal melanoma

Shanna DewaeleBoel De PaepeLouis DelhayeEric de Bony de LavergneJilke De WildeKatrien VanderheydenJasper AnckaertNurten YigitEveline Vanden EyndeFariba Nemati et al.

mTor inhibitor GDC-0349 improves ASO induced SAMMSON knock down resulting in enhanced anti-tumor efficacy in uveal melanoma

Shanna DewaeleBoel De PaepeLouis DelhayeEric de Bony de LavergneJilke De WildeKatrien VanderheydenJasper AnckaertNurten YigitEveline Vanden EyndeFariba Nemati et al.

2019

RNA-directed proteomics to explore the interactome of the melanoma-specific lncRNA SAMMSON

Louis DelhayeShanna DewaeleDelphine De SutterPieter MestdaghSven Eyckerman

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeLouis DelhayeFariba NematiDidier DecaudinSven EyckermanRudy Van CosterJo VandesompelePieter Mestdagh

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeLouis DelhayeFariba NematiDidier DecaudinSven EyckermanRudy Van CosterJo VandesompelePieter Mestdagh

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeLouis DelhayeFariba NematiDidier DecaudinSven EyckermanRudy Van CosterJo VandesompelePieter Mestdagh

2018

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeFariba NematiSergio Roman RomanRudy Van CosterJo VandesompelePieter Mestdagh

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeFariba NematiSergio Roman RomanRudy Van CosterJo VandesompelePieter Mestdagh

2017

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenBoel De PaepeFariba NematiSergio Roman RomanRudy Van CosterJo VandesompelePieter Mestdagh

Therapeutic applications of SAMMSON lncRNA inhibition in uveal melanoma

Shanna DewaeleKatrien VanderheydenJo VandesompelePieter Mestdagh